TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* osteosarcoma~* eligible to receive 2 sequential cycles of HDMTX-LV~Exclusion Criteria:~* prior administration of glucarpidase~* progression of disease while on previous MTX treatment

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): HDMTX-LV with glucarpidase
- B (Type: ACTIVE_COMPARATOR): HDMTX-LV with placebo
- C (Type: EXPERIMENTAL): compassionate use group to treat or prevent life threatening toxicity in the event of delayed elimination of MTX and/or renal impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electric Muscle Stimulation for Patients With Chronic Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient required mechanical ventilation more than 14 days~* No ability for active endurance exercise because of poor consciousness or limb weakness.~Exclusion Criteria:~* Pregnant women~* Limb wound/infection interfered with electric pad application~* Recent acute myocardial infarction or life-threatening arrhythmia~* Uncontrolled epilepsy~* Dying patients without attempt of ventilator weaning~* Absence of respiratory drive

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Electric muscle stimulation(EMS) (Type: EXPERIMENTAL): EMS:use programmed middle frequency electric stimulation device(HELEX 573)for both quadriceps stimulation, 32 minutes per day, 5 time per week.
- Control (Type: NO_INTERVENTION): Patients with routine passive rehabilitation program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 year-old~* Indication carpal tunnel release surgery of idiopathic carpal tunnel syndrome.~* To agree to participate (signature of the informed consent)~* Affiliate or beneficiary of a social security scheme~Exclusion Criteria:~* Patients with non-idiopathic carpal tunnel syndrome with medical contraindication : pregnancy, obesity (body mass index \> 30), diabetes, rheumatoid arthritis, sarcoidosis, purulent tenosynovitis, tuberculosis, systemic lupus erythematosus, hypothyroidism or hyperthyroidism and gout.~* Patients with history of cardiac disease or coronary artery disease.~* Patients with systemic amyloidosis already known.~* Patients unde guardianship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Physical Activity as an Aid for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Current daily smoker \>10 or more cigarettes per day~2. Having smoked (on average \> 10 cigarettes/day) regularly for at least 3 years~3. Age between 18 and 65 years~4. Sedentary lifestyle defined as less than 20 minutes a day of moderate-intensity physical assessed by the Swiss Baseline Questionnaire.~Exclusion Criteria:~1. Current pharmacological agent use to quit smoking~2. Medical problems that would alter training responses: arthritis, heart disease, and orthopedic problems~3. Presence of an unstable medical condition~4. Current or recent major cardiovascular event, such as recent myocardial infarction (\>12 months) or stroke, angina pectoris, major arrhythmia~5. Current psychiatric illness~6. Alcohol (\> 4 drinks/day for men and \> 3 drink/d. for women), or/and other substance abuse~7. Current or planned pregnancy~8. Systematic skin disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): a tailored physical activity intervention involving moderate-intensity exercise
- B (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Can Magnetic Brain Stimulation Help Prevent Relapse in Depression?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Major Depressive Disorder~* Patients who are not actively receiving any psychotherapy~* Patients who are on no or only one antidepressant~Exclusion Criteria:~* History of a psychotic episode~* History of neurological illness~* Previous head injury~* Active alcohol or substance abuse~* History of seizure disorders~* Currently pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cluster rTMS (Type: EXPERIMENTAL): Two weeks of daily repetitive Transcranial Magnetic Stimulation (total of 10 rTMS sessions), six months following completion of regular six-week rTMS treatment.
- Taper rTMS (Type: EXPERIMENTAL): Immediately following completion of regular six-week repetitive Transcranial Magnetic Stimulation treatment, patients in this group will receive three sessions of rTMS a week for two weeks followed by two sessions of rTMS a week for two weeks (total of 10 rTMS sessions tapered in 4 weeks)
- Treatment as Usual (Type: EXPERIMENTAL): Following their last session of regular six-week rTMS treatment, patients in this group will follow an individually-tailored maintenance plan as determined by their own psychiatrist or primary care provider

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Corneal thickness ≥ 400 µm~* Progressive stage 1 to 3 keratoconus (Krumeich classification)~Exclusion Criteria:~* Corneal thickness \< 400µm~* Stage 4 keratoconus (Krumeich classification)~* Concomitant corneal disease~* History of corneal surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iontophoretic CXL (Type: EXPERIMENTAL): The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
- Standard CXL (Type: ACTIVE_COMPARATOR): In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Economic Impact of Four Varieties of Mesh Inguinal Hernia Repair- a Double-Blinded, Prospective, Randomized Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Unilateral primary inguinal hernia presenting for repair~Exclusion Criteria:~* Recurrent repairs~* Females~* Bilateral repairs~* Repairs done with other operative procedures

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): None
- 2 (Type: None): None
- 3 (Type: None): None
- 4 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ulipristal Acetate 10 mg and Asisted Reproduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients\> 18 and \<50 years Patients who undergo a first / second cycle OVD Patients who present within 1-3 intramural myomas\> 2 cm and \<5 cm that do not distort the cavity, Type 3 and 4 of the FIGO classification (Figure 1). Miomas inoperable for medical judgment or patient desire, you want to avoid the post-surgical time waiting 6 months / 1 year before you can submit to TRA Patients who have undergone previous myomectomy who prefer to avoid having surgery~Exclusion Criteria:~History of endometrial changes in patients (hyperplasia) Presence of other endometrial pathologies: polyps, scars of previous cesarean complicated adenomyosis foci, suspected adhesions Simultaneous participation in another clinical study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Ulipristal Acetate 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
- Control (Type: PLACEBO_COMPARATOR): Placebo, 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: aHUS Observational Long Term Follow-Up

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* aHUS patients who participated in any one of the aHUS-eculizumab clinical studies.~* aHUS patients or legal representative who are able and willing to given written informed consent for their study information to be collected and retained in a database.~Exclusion Criteria:~* Not applicable.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age~* corneal transplant recipient with intraocular pressure (IOP) greater than 24 mmHg and with relative increase in IOP of at least 10 mmHg over the pre-graft baseline~Exclusion Criteria:~* not pregnant or lactating~* intraocular surgery in the study eye within 30 days before enrolling in the study~* use of any investigational drug or treatment within 30 days before receipt of study medication~* clinical evidence of scleral thinning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 mg anecortave acetate (Type: ACTIVE_COMPARATOR): None
- 15 mg anecortave acetate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients \>/=18 years of age.~2. Patients must be engrafted and at least 80 days post allogeneic hematopoietic stem cell transplantation.~3. New onset airflow obstruction defined as decline of forced expiratory volume in 1 second (FEV1) percent predicted \>/= 15%.~4. Total Lung Capacity (TLC) \> 85% to rule out restrictive lung disease.~5. Patient must be willing to comply with all study procedures and capable of signing informed consent.~Exclusion Criteria:~1. Patients with active pulmonary infection.~2. Patients with known hypersensitivity to corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone Propionate (Type: EXPERIMENTAL): 440 micrograms twice daily by oral inhalation.
- Observational Group (Type: NO_INTERVENTION): Comparator group, no intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Both genders~* For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation.~* Written consent after information provided by the patient or the legal representative in the event that the patient cannot consent.~* Upper respiratory or lower respiratory tract infection, as in Annexes II and III respectively.~* Positive respiratory secretion test for SARS-CoV-2 virus by molecular techniques or positive blood IgM titers.~Exclusion Criteria:~* Under 18 years of age~* Denial of written consent~* Any patient case where it has been decided not to rejuvenate~* Serum AST values greater than 5 times the upper normal range~* QTc interval in rest electrocardiogram greater than 500msecs~* Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- UNIKINON (Chloroquine phosphate) (Type: EXPERIMENTAL): Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological confirmation of recurrent or metastatic HNSCC~* Measurable disease as defined by RECIST v1.1~* PD-L1 positive~Exclusion Criteria:~* Diagnosis of recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary histology; or salivary gland or non-squamous histologies (e.g. mucosal melanoma)~* Disease amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)~* Prior systemic anti-cancer therapy (use of chemotherapeutic agents, targeted small molecules, immunotherapy, or monoclonal antibodies) for the treatment of recurrent or metastatic HNSCC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADU-S100 and pembrolizumab (Type: EXPERIMENTAL): All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of breast cancer treated by conservative surgery .~* Normal inclusion radiological assessment normal (ACR1 or ACR2)~* Moderate Deformations (Type I and II of the classification of Clough).~* Delay with regard to the end of the radiotherapy superior or equal to one-year-old.~* Moderated radio-dystrophies (\< Grade 2 of the score LENT/SOMA).~* Signature of the informed consent~* Patient benefiting from social security~* Patient of more than 18 years old~Exclusion Criteria:~* Abnormal radiological assessment (ACR3, ACR4 or ACR5)~* Absence of fatty excess .~* radio surgical relapses with vast fibroses of the breast (\> Grade 2 of the score LENT/SOMA).~* Patient under 18 years old.~* administrative difficulties: impossibility to provide enlightened information to the patient, the refusal to sign the consent .~* pregnant women or breast feeding women~* patient under legal guardianship~* bilateral breast cancer regardless histologic type.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- surgery by fatty tissue transfer (Type: EXPERIMENTAL): None
- simple supervision (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Short-term Behavior Change With Pedal Desk Installation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be a full-time employee at Pennington Biomedical Research Center~* Be between 21 and 65 years of age~* Primarily sit while at work~* Work from a private office/cubicle~Exclusion Criteria:~* Weigh more than 250 pounds~* Have physical limitations that prevent performance of pedaling motions~* Plan to be away from work for the 6 weeks of the intervention~* Be pregnant~* Have a pace maker and/or metal joint replacement~* Plan to be away from work for the 6 weeks of the intervention

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Pedal Desk (Type: OTHER): Participants will complete three 2-week conditions in the following order:~1. Self-directed Pedal Desk~2. Facilitated Pedal Desk~3. Facilitated Pedal Desk with Pedometer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: ROMEO®2 PAD. 2 YEARS PROSPECTIVE FOLLOW-UP

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Surgical treatment of stenosis and Grade I degenerative spondylolisthesis, secondary to lumbar degenerative disc disease at one level between L1 and L5 in skeletally mature patients~Exclusion Criteria:~* Vertebral traumatic lesions including dislocation;~* Insufficient vertebral body bone quality;~* Severe osteoporosis;~* Bone tumor in the region of the implant;~* Spondylolysis;~* Lytic spondylolisthesis;~* Degenerative spondylolisthesis Grade II or more;~* Mental illness or inadequate patient activity;~* Infection;~* Vascular disorders or illness;~* Pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues